9. Quest for CURES
“With evolving technologies and emerging treatment options, this RFP is focused on defining subgroups of patients with a given diagnosis, understanding the role and improving detection of minimal residual disease (MRD) in hematological malignancies and using this information to guide treatment intervention,” explain the LLS about Quest for CURES, which is funded together with Celgene.
